| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Volker Vallon | Q61090162 |
| P2093 | author name string | Kumar Sharma | |
| P2860 | cites work | Renal Na(+)-glucose cotransporters | Q28141135 |
| The sodium/glucose cotransport family SLC5 | Q28204259 | ||
| Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2) | Q28215167 | ||
| Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats | Q46166885 | ||
| Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects | Q46171594 | ||
| Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats | Q46406143 | ||
| Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models | Q46516165 | ||
| Oxidative stress pathway genes and chronic renal insufficiency in Asian Indians with Type 2 diabetes | Q46644155 | ||
| Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes | Q46764321 | ||
| Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes | Q46818617 | ||
| Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. | Q46930511 | ||
| Adenosine A(1) receptors determine glomerular hyperfiltration and the salt paradox in early streptozotocin diabetes mellitus | Q63384113 | ||
| Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy | Q69530391 | ||
| Predicting diabetic nephropathy in insulin-dependent patients | Q71401816 | ||
| Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption | Q73253331 | ||
| T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats | Q74210650 | ||
| T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes | Q78238839 | ||
| Expression and activity of SGLT2 in diabetes induced by streptozotocin: relationship with the lipid environment | Q83717092 | ||
| A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria | Q28299174 | ||
| Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095 | Q28346436 | ||
| Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes | Q28346536 | ||
| Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney | Q28580452 | ||
| SLC2A2 gene expression in kidney of diabetic rats is regulated by HNF-1alpha and HNF-3beta | Q28583067 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. | Q33242098 | ||
| Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians | Q33281836 | ||
| Association analysis of ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1 gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes | Q33547739 | ||
| Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
| Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney | Q33897182 | ||
| The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose | Q34121476 | ||
| Diabetic kidney disease in thedb/dbmouse | Q34195384 | ||
| Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1) | Q34264473 | ||
| Oral antihyperglycemic therapy for type 2 diabetes: scientific review | Q34492673 | ||
| Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level | Q34575066 | ||
| Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view. | Q35049884 | ||
| Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. | Q35060202 | ||
| Phlorizin: a review | Q35995949 | ||
| Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment | Q36785571 | ||
| Diabetes and chronic kidney disease: lessons from the Pima Indians | Q37102238 | ||
| Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes | Q37139427 | ||
| A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment | Q37319128 | ||
| Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. | Q37645623 | ||
| Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats | Q39999985 | ||
| Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing | Q41990239 | ||
| (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment | Q43123822 | ||
| Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study | Q43143768 | ||
| Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus | Q43199877 | ||
| In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans | Q43227334 | ||
| Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats | Q43267686 | ||
| Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. | Q43669733 | ||
| Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy. | Q43814835 | ||
| Long-term outcome of renal glucosuria type 0: the original patient and his natural history | Q45010378 | ||
| A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria | Q45117069 | ||
| High glucose-induced oxidative stress inhibits Na+/glucose cotransporter activity in renal proximal tubule cells | Q45187170 | ||
| TGF-beta impairs renal autoregulation via generation of ROS. | Q45220024 | ||
| Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats | Q45763147 | ||
| Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. | Q45926087 | ||
| P433 | issue | 5 | |
| P921 | main subject | glucose | Q37525 |
| glycobiology | Q899224 | ||
| P304 | page(s) | 425-431 | |
| P577 | publication date | 2010-09-01 | |
| P1433 | published in | Current Opinion in Nephrology and Hypertension | Q15756282 |
| P1476 | title | Sodium-glucose transport: role in diabetes mellitus and potential clinical implications | |
| P478 | volume | 19 |
| Q38537119 | A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans |
| Q37887401 | Antifibrotic treatment and other new strategies for improving renal outcomes |
| Q36836209 | Aquaporin 11 insufficiency modulates kidney susceptibility to oxidative stress. |
| Q27021632 | Early diabetic nephropathy in type 1 diabetes: new insights |
| Q34579919 | Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy? |
| Q38735470 | Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes. |
| Q37575461 | Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. |
| Q35392355 | Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice |
| Q36527897 | Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus |
| Q42575158 | Molecular determinants of renal glucose reabsorption. Focus on “Glucose transport by human renal Na+/d-glucose cotransporters SGLT1 and SGLT2” |
| Q35612377 | Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion |
| Q38111707 | Pathophysiology of the diabetic kidney. |
| Q37729725 | Patient considerations in the management of type 2 diabetes - critical appraisal of dapagliflozin |
| Q41295481 | Proximal tubule cell hypothesis for cardiorenal syndrome in diabetes |
| Q37253944 | Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney |
| Q37575455 | SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. |
| Q34400029 | SGLT2 inhibitors act from the extracellular surface of the cell membrane |
| Q38783130 | Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. |
| Q90514635 | Sodium-glucose Co-transporters: Functional Properties and Pharmaceutical Potential |
| Q38164537 | Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? |
| Q27015001 | Sodium-retaining effect of insulin in diabetes |
| Q45189238 | Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats. |
| Q38126109 | The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors |
| Q37712484 | The prelude on novel receptor and ligand targets involved in the treatment of diabetes mellitus. |
| Q34979592 | The proximal tubule in the pathophysiology of the diabetic kidney |
| Q30663494 | The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment |
| Q37838893 | The role of metabolic and haemodynamic factors in podocyte injury in diabetes |
Search more.